Bibliography
- BRYSKIER A: Cephems: fifty years of continuous research. j Antibiotics. (2000) 53(10):1028–1037.
- ••Excellent review on the structure-activityrelationships arising from cephalosporin modifications.
- SYKES RB, BONNER DP, SWABB EA: Modern P-lactam antibiotics. In: Antibiotic Inhibitors of Bacterial Cell Wall Biosynthesis. Tipper DJ (Ed.), Pergamon Press, New York, USA (1987):171–197.
- LIVERMORE DM: Interplay of impermeability and chromosomal p-lactamase in imipenem-resistant Pseudomonas aeruginosa. Antlinicrob. Agensts Chernother. (1992) 36(9):2046–2048.
- SRIKUMAR R, TSANG E, POOLE K: Contribution of the MexAB-OprM multidrug efflux system to the beta-lactam resistance of penicillin-binding proteitn and beta-lactamase-derepressed mutants of Pseudomonas aeruginosa. j Antlinicrob. Chernother. (1999) 44(4):537–540.
- MEDERIOS AA: Evolution and dissemination of P-lactamases accelerated by generation of P-lactam antibiotics. Clin Infect. Dis. (1997):24(Supm. 1):S19–S45.
- ••A very thorough review on p-lactam actionand p-lactamases.
- RICE LB: Successful interventions for Gram-negative resistance to extended-spectrum P-lactam antibiotics. Phannacotherapy (1999) 19(8 Pt 2):1205-128S.
- LIVERMORE DM, WOODFORD N: Carbapenemases: a problem in waiting. Curr. Opin. Microbial (2000) 3(5):489–495.
- ••Comprehensive summary of chromosomal-and plasmid-mediated carbapenemases.
- NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS (NCCLS): Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: Approved standard M7-A5. NCCLS, Wayne, Pennsylvania, USA (2000).
- BUSH K: New P-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. an. Infect. Dis. (2001) 32(7):1085–1089.
- ••Excellent synopsis of the ever-expandinglist of P-lactamases.
- WINOKUR PL, CANTON R, CASSELLAS J-M, LEGAKIS N: Variations in the prevalence of strains expressing an extended-spectrum P-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. an. Infect. Dis. (2001) 32\(Suppl. 2):594–5103.
- GO ES, URBAN C, BURNS J et al: Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet (1994) 344(8933):1329–1332.
- CARMELI Y, TROILLET N, GLIOPOOULOS GM, SWORE MH: Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antlinicrob. Agents Chernother. (1999) 43(6):1379–1382.
- SANYAL SC, MOKADDAS EM: The increase in carbapenem use and emergence of Sterratraphomorras maltaphilia as an important nosocomial pathogen. Chernother. (1999) 11(1):28–33.
- CHAMBERS HF: Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbial. Rev (1997) 10(4):781–791.
- •A good review of clinical microbiology testing aspects using p-lactams against MRSA strains.
- CHAMBERS HF: The changing epidemiology of Staphylococcus aureus. Emerg. Infect. Dis. (2001) 7(2):178–182.
- ••Convincing speculation that if the trends inhospital and community prevalence rates of MRSA follow those observed with penicillinase-producing, methicillin-susceptible S. aureus strains in the 1950 to 1970s, MRSA within the community may increase, particularly if nosocomial MRSA rates exceed 40-50%. Rates of MRSAs from ICUs already have approached the 50% mark.
- MORENO F, DRISP C, JORGENSEN JH, PATTERSON JE: Methicillin-resistant Staphylococcus aureus as a community organism. an. Infect. Dis. (1995) 21(5):1308–1312.
- HAROLD BC, IMMERGLUCK LC, MARANAN MC et al.: Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA (1998) 279:593–598.
- FUCHS PC, BARRY AL, BROWN SD: In-vitro antimicrobial activity of a carabapenem, MK-0826 (L-749,345) and provisional interpreative criteria for disc tests. j Antlinicrob. Chernother. (1999) 43(5):703–706.